Crossmark

Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study

Crossref DOI link: https://doi.org/10.1016/j.bjid.2022.102697

Published Print: 2022-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Pereira, Gustavo H. http://orcid.org/0000-0003-2768-9605
Peixoto, Helena R. http://orcid.org/0000-0002-7598-4361
Giusti, Mariana L. http://orcid.org/0000-0002-1270-7236
Souza, Mariana L. http://orcid.org/0000-0002-2288-165X
Victor, Livia B. http://orcid.org/0000-0003-0773-7913
Fernandes, Flávia http://orcid.org/0000-0002-3149-3667
Perez, Renata M. http://orcid.org/0000-0002-3367-9991
Villela-Nogueira, Cristiane A. http://orcid.org/0000-0003-1355-2368
License Information

Text and Data Mining valid from 2022-09-01

Text and Data Mining valid from 2022-09-01

Version of Record valid from 2022-08-13
More Information

This article is maintained by: Elsevier

Article Title: Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study

Journal Title: The Brazilian Journal of Infectious Diseases

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.bjid.2022.102697

Content Type: article

Copyright: © 2022 Published by Elsevier España, S.L.U. on behalf of Sociedade Brasileira de Infectologia.

Document is current

Any future updates will be listed below